Products
Aducanumab has been studied in phase III trials and is in the pre-approval phase. The drug is not yet commercially available. The trials were discontinued in March 2019. However, following a re-analysis, the company announced in October 2019 that it expected to file for approval. Apparently, a sufficiently high dose is required for an effect to occur.
Structure and properties
Aducanumab is a human IgG1 monoclonal antibody. It is produced by biotechnological methods.
Effects
Aducanumab crosses the blood–brain barrier and selectively binds to both soluble and insoluble beta-amyloid. It leads to a significant reduction in beta-amyloid and plaques in the brain.
Indications
Aducanumab was developed for the treatment of early Alzheimer’s disease.
Dosage
According to the SmPC. In clinical trials, the drug was administered once monthly as an intravenous infusion.
